NASDAQ: ADTXAditxt Inc Stock
$2.37+0.10 (+4.41%)
Updated Apr 24, 2024
ADTX Price
$2.37
Fair Value Price
N/A
Market Cap
$3.95M
52 Week Low
$2.14
52 Week High
$68.08
P/E
-0.02x
P/B
0.25x
P/S
3.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$645.18k
Earnings
-$32.38M
Gross Margin
-17.3%
Operating Margin
-4,368.69%
Profit Margin
-5,068.5%
Debt to Equity
1.78
Operating Cash Flow
-$19M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADTX Overview
Aditxt, Inc. is a biotech company developing technologies to improve the health of the immune system by mapping and reprogramming. Its products, AditxtScore and Apoptotic DNA Immunotherapy, mimic the way the body naturally induces tolerance. Aditxt is also developing organ transplant products. The company has a license agreement with Loma Linda University. It was known as ADiTx Therapeutics, Inc. until it changed its name in 2021/07. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, VA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADTX is good value based on its book value relative to its share price (0.25x), compared to the US Biotechnology industry average (5.86x)
P/B vs Industry Valuation
ADTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ADTX due diligence checks available for Premium users.
Be the first to know about important ADTX news, forecast changes, insider trades & much more!
ADTX News
Valuation
ADTX fair value
Fair Value of ADTX stock based on Discounted Cash Flow (DCF)
Price
$2.37
Fair Value
$6.69
Undervalued by
64.58%
ADTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
15.69x
Market
41.27x
ADTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.25x
Industry
5.86x
ADTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADTX's financial health
Profit margin
Revenue
$81.3k
Net Income
-$11.0M
Profit Margin
-13,679.4%
ADTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$44.6M
Liabilities
$28.5M
Debt to equity
1.78
ADTX's short-term liabilities ($25.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADTX's short-term assets ($6.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$0.0
Financing
$1.8M
ADTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADTX vs Biotech Stocks
Aditxt Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.